Clinical Research

Eli Lilly and Co reported positive results for its Alzheimer’s disease drug donanemab on 3 May saying that the Phase 3 TRAILBLAZER-ALZ 2 trial met the primary and all secondary endpoints measuring cognitive and functional decline. The company expects to make a regulatory submission to the US Food and Drug Administration by 30 June. Lilly submitted a regulatory application for donanemab to the FDA in January but the agency turned it back citing insufficient data.

Just a year after closing a €60 million Series B financing, Tubulis GmbH of Germany has concluded a licensing agreement with Bristol Myers Squibb Company to develop antibody-drug conjugates (ADC). Announced on 20 April, the deal will give BMS rights to Tubulis’ technology platform to develop ADCs for solid tumours. The number of products to be developed wasn’t disclosed.

The Food and Drugs Authority (FDA) of Ghana has approved a vaccine developed by the University of Oxford, UK, to prevent malaria – the first regulatory clearance for the product globally. The vaccine, R21/Matrix-M, is a subunit vaccine made up of a protein secreted by the malaria parasite and fused to a fragment of the hepatitis B virus. It is delivered alongside a plant-based adjuvant that enhances a person’s immune response. The adjuvant was developed by Novavax Inc of the US. The vaccine is being manufactured and scaled up by the Serum Institute of India PvT Ltd.

Dupixent (dupilumab), a monoclonal antibody approved to treat asthma, atopic dermatitis and three other inflammatory diseases, has now been shown to be effective in chronic obstructive pulmonary disease (COPD), the third leading cause of death in the world. Results of a Phase 3 trial of the drug showed that it achieved a 30% reduction in moderate or severe acute exacerbations in COPD, Sanofi SA announced on 23 March. Dupixent is being jointly developed by Sanofi and Regeneron Pharmaceuticals Inc.

Acesion Pharma ApS of Denmark has reported that proof-of-mechanism has been achieved in a Phase 2 trial of patients with atrial fibrillation who were treated with its SK ion channel inhibitor. The drug, AP30663 is intended to convert atrial fibrillation, the most common cardiac arrhythmia, into a normal sinus rhythm. This is achieved through SK channel inhibition.

The Food and Drug Administration is to allow Intellia Therapeutics Inc to include the US in its global trial of a genome editing therapy for hereditary angioedema (HAE), a rare protein deficiency that can cause swelling in multiple parts of the body. To date, the Phase 1/2 study has been taking place at sites in the Netherlands, New Zealand and the UK. The addition of sites in the US will increase the geographical reach of the programme, as well as the number of patients receiving the experimental therapy. Intellia is based in Cambridge, US.

Bolstered by $60 million in receipts from a private share placement, Immunic Inc ended 2022 with cash and investments of $116.4 million, enabling it to fund the clinical development of its products for multiple sclerosis, psoriasis, and celiac disease into the fourth quarter of 2024. The financing, completed in October 2022, was supported by new and existing investors including Deep Track Capital, Commodore Capital and BVF Partners LP.

Long-term data from two Phase 3 trials of Cosentyx (secukinumab), an approved drug for plaque psoriasis and other inflammatory indications, have shown sustained efficacy and symptom improvement in patients with hidradenitis suppurativa (HS). HS is a recurrent skin disease causing abscesses that can lead to wounds and scarring. The two trials enrolled more than 1,000 patients in 40 countries.

The Roche Group has reported positive data from a Phase 3 programme of the monoclonal antibody crovalimab in people with paroxysmal nocturnal haemoglobinuria (PNH), a rare and life-threatening blood condition. PNH occurs when red blood cells are destroyed by the complement system, part of the innate immune system. Participants in the second of two studies had not been previously treated with complement inhibitors.

An antibody drug developed by Boehringer Ingelheim GmbH to prevent flares in generalised pustular psoriasis (GPP), a rare skin disease, has met its primary and key secondary endpoints in a Phase 2b trial of patients with the disease. Spesolimab (Spevigo) has already been approved for the treatment of the disease.